Endocrinology

An analysis of 3 academic health centers suggests youth with diabetic retinopathy had a longer duration of diabetes and higher hemoglobin A1c at the time of the diabetic eye exam.

Juan Frias, MD, discusses the potential impact of an FDA approval for once-weekly insulin icodec based on data observed within the ONWARDS program.

At ADA 2023, we asked interview guests for their opinions on the most important news to come from this year's scientific sessions, including Juan Frias, MD, Bob Gabbay, MD, PhD, Yehuda Handelsman, MD, Viral Shah, MD, and more.

A new analysis presented at ADA 2023 recommended effective diabetic retinopathy screening for patients with T2D and hypertension.

A direct comparison of 3 independent AI systems showed differing prevalences of diabetic retinopathy, suggesting inconsistencies when applying these tools to those without preexisting diabetes.

Announced on June 28, 2023, the FDA's approval of donislecel (Lantidra) marks the first approval of an allogeneic pancreatic islet cellular therapy for the treatment of type 1 diabetes.

The analysis, from ADA 2023, additionally indicated SGLT2 inhibition showed no effect on the risk of requiring intravitreal injection treatment for DME.

Use of metformin was associated with significant reductions in the risk of developing POAG beyond glycemic control, according to an analysis presented at ADA 2023.

APX3330 showed statistically significant prevention of ≥3-step binocular DRSS worsening compared to placebo, but did not meet the study's primary endpoint.

In an interview at ADA 2023, Aggarwal discusses the efficacy of sotagliflozin on heart failure-related outcomes independent of A1c and the greater implications of these findings.

A new analysis from ADA 2023 suggests positive discordance according to GMI/A1c ratios was associated with an increased risk for diabetic retinopathy.

New results from the ongoing clinical trial of VX-880 suggested all patients with T1D treated with the novel stem cell-derived islet cell therapy showed restored endogenous insulin secretion and improved glycemic control.

According to new data presented at ADA 2023, patients with T2D experience an increased risk of incident retinopathy per 1-SD increase in glycemia risk index.

A new analysis presented at ADA 2023 suggests a machine learning algorithm may refine the risk of diabetic retinopathy progression and personalize screening intervals for patients.

Research presented at ADA 2023 suggests early glycemic screening in high-risk children may predict future diabetes-related complications, including retinopathy and nephropathy.

Data from a phase 2 dose-finding trial from ADA 2023 suggests use of survodutide was associated with a mean body weight reduction of 14.9% at 46 weeks, with 67% of people using survodutide 4.8 mg losing 15% or more of their baseline body weight.

An analysis of data from the NYC A1C Registry suggests women with gestational diabetes were more likely to develop diabetes after giving birth and were also more likely to have difficulty achieving glycemic control after diagnosis.

The FDA's historic June 20, 2023 approval of empagliflozin (Jardiance) and empagliflozin plus metformin hydrochloride (Synjardy) marks the first pediatric type 2 diabetes indication for the SGLT2 inhibitor class and comes less than a year after the debut of DINAMO data.

An analysis provided updated estimates of the US prevalence of DR and VTDR, showing that 9.6 million people had DR and 1.84 million people had VTDR in 2021.

An ENDO 2023 analysis of data suggests women with PCOS were at a 47% greater risk of mortality relative to their counterparts without the common endocrine disorder.

The analysis of the DRCR Retina Network Protocol AC suggested cost savings occur with bevacizumab-first step therapy in eyes with DME, but the magnitude might not be as great as previously understood.

Additional phase 4 trial results presented at ENDO 2023 reinforce the efficacy and safety of teprotumumab-trbw in eyes with TED, regardless of disease activity or duration.

Based on the results of 2 studies, lower birthweight was associated with younger age, lower prevalence of obesity, and fewer individuals with a family history of T2D.

The investigative team observed a U-shaped relationship between sleep duration and incident diabetes, with the greatest risk when sleep duration was ≥10 hours per day.

Research presented at ENDO 2023 suggests a high number of adults in the United States with normal BMI still have obesity.

This endocrine case report from Brady Pregerson, KMD, features a woman in her mid-30s with a history of cerebral astrocytoma status post radiation therapy presenting with generalized weakness, a gradual onset generalized headache, and excessive thirst. Can you determine the correct diagnosis?

Data from the COVID-OUT trial suggests use of metformin could reduce a person's risk of developing long COVID by more than 50% relative to placebo therapy, with results also providing insight into the apparent lack of benefit with ivermectin and fluvoxamine.

The ongoing shortage of GLP-1 receptor agonists, namely semaglutide, has prompted the US Food and Drug Administration to issue a warning to patients and providers related to use of compounded semaglutide.

12-month adherence to GLP1-RA or SGLT2i therapies was highest among individuals with T2D and/or heart failure with a low prescription co-payment.

Each month, our editorial staff compiles a recap of the top news in endocrinology from the past month. Our May 2023 month in review features new FDA approvals, important phase 2 data, and in-depth clinician perspective.